NASDAQ:ANIK - Anika Therapeutics Stock Price, Forecast & News

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

Anika Therapeutics Inc (NASDAQ:ANIK) released its quarterly earnings results on Thursday, October, 24th. The biotechnology company reported $0.64 EPS for the quarter, beating analysts' consensus estimates of $0.39 by $0.25. The biotechnology company earned $29.70 million during the quarter, compared to analyst estimates of $27.01 million. Anika Therapeutics had a return on equity of 11.59% and a net margin of 27.60%. Anika Therapeutics's quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.53 EPS. View Anika Therapeutics' Earnings History.

Anika Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Anika Therapeutics.

5 brokerages have issued 12 month price objectives for Anika Therapeutics' shares. Their forecasts range from $29.00 to $65.00. On average, they expect Anika Therapeutics' share price to reach $50.50 in the next twelve months. This suggests a possible upside of 8.8% from the stock's current price. View Analyst Price Targets for Anika Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating, 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Anika Therapeutics.

News headlines about ANIK stock have trended positive this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Anika Therapeutics earned a coverage optimism score of 2.5 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Anika Therapeutics.

Some companies that are related to Anika Therapeutics include Align Technology (ALGN), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), West Pharmaceutical Services (WST), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), Quidel (QDEL), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), Antares Pharma (ATRS), Cerus (CERS), OraSure Technologies (OSUR) and Meridian Bioscience (VIVO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Celgene (CELG), Gilead Sciences (GILD), Baidu (BIDU), Biogen (BIIB), NVIDIA (NVDA), Skyworks Solutions (SWKS), ACADIA Pharmaceuticals (ACAD) and Netflix (NFLX).

Anika Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Boston Trust Walden Corp (1.54%), State of Alaska Department of Revenue (0.08%) and Welch & Forbes LLC (0.03%). Company insiders that own Anika Therapeutics stock include Glenn R Larsen, Jeffery S Thompson, Joseph G Darling, Joseph L Bower, Raymond J Land and Sylvia Cheung. View Institutional Ownership Trends for Anika Therapeutics.

ANIK stock was sold by a variety of institutional investors in the last quarter, including Boston Trust Walden Corp. Company insiders that have sold Anika Therapeutics company stock in the last year include Glenn R Larsen, Jeffery S Thompson, Joseph L Bower, Raymond J Land and Sylvia Cheung. View Insider Buying and Selling for Anika Therapeutics.

ANIK stock was purchased by a variety of institutional investors in the last quarter, including Welch & Forbes LLC and State of Alaska Department of Revenue. View Insider Buying and Selling for Anika Therapeutics.

Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ANIK stock can currently be purchased for approximately $46.42.

Anika Therapeutics has a market capitalization of $662.37 million and generates $105.56 million in revenue each year. The biotechnology company earns $18.72 million in net income (profit) each year or $1.84 on an earnings per share basis. Anika Therapeutics employs 133 workers across the globe.View Additional Information About Anika Therapeutics.

The official website for Anika Therapeutics is http://www.anikatherapeutics.com/.

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected]